Insight Molecular Diagnostics (IMDX) Short term Debt: 2020-2025
Historic Short term Debt for Insight Molecular Diagnostics (IMDX) over the last 5 years, with Sep 2025 value amounting to $1.1 million.
- Insight Molecular Diagnostics' Short term Debt rose 71.99% to $1.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.1 million, marking a year-over-year increase of 71.99%. This contributed to the annual value of $228,000 for FY2024, which is 90.15% down from last year.
- According to the latest figures from Q3 2025, Insight Molecular Diagnostics' Short term Debt is $1.1 million, which was up 53.27% from $689,000 recorded in Q2 2025.
- In the past 5 years, Insight Molecular Diagnostics' Short term Debt ranged from a high of $11.7 million in Q2 2021 and a low of $109,000 during Q3 2022.
- In the last 3 years, Insight Molecular Diagnostics' Short term Debt had a median value of $523,500 in 2024 and averaged $694,000.
- Per our database at Business Quant, Insight Molecular Diagnostics' Short term Debt plummeted by 95.13% in 2022 and then skyrocketed by 2,022.94% in 2023.
- Quarterly analysis of 5 years shows Insight Molecular Diagnostics' Short term Debt stood at $1.4 million in 2021, then crashed by 92.15% to $109,000 in 2022, then skyrocketed by 2,022.94% to $2.3 million in 2023, then slumped by 90.15% to $228,000 in 2024, then surged by 71.99% to $1.1 million in 2025.
- Its Short term Debt was $1.1 million in Q3 2025, compared to $689,000 in Q2 2025 and $433,000 in Q1 2025.